RO118564B1 - Compoziţie farmaceutică de aerosol - Google Patents

Compoziţie farmaceutică de aerosol

Info

Publication number
RO118564B1
RO118564B1 RO97-00561A RO9700561A RO118564B1 RO 118564 B1 RO118564 B1 RO 118564B1 RO 9700561 A RO9700561 A RO 9700561A RO 118564 B1 RO118564 B1 RO 118564B1
Authority
RO
Romania
Prior art keywords
aerosol composition
weight
pharmaceutical aerosol
composition
ochch
Prior art date
Application number
RO97-00561A
Other languages
English (en)
Inventor
Li Li-Bovet
Keith Arthur Johnson
Original Assignee
Glaxo Wellcome Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc. filed Critical Glaxo Wellcome Inc.
Publication of RO118564B1 publication Critical patent/RO118564B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Prezenta invenţie se referă la o compoziţie farmaceutică de aerosol, pentru utilizarea în administrarea medicamentelor prin inhalare, în tratamentul medical. Compoziţia farmaceutică de aerosol, conform invenţiei, cuprinde 0,005 până la 10% în greutate din unul sau mai multe medicamente sub formă de particule, raportat la greutatea totală a compoziţiei, unul sau mai mulţi agenţi propulsori pe bază de fluorocarburi sau clorofluorocarburi, care conţin hidrogen, şi 0,05 până la 15% în greutate, raportat la medicament, dintr-un agent tensioactiv cu formula generală Ia sau Ib: în care Rreprezintă: R-(CH)-(CH=CH)-(CH)-(CH=CH)-(CH)-A-; R-(CH)-OCHCH(CHOH)-CH-A-; R-(CH)g-OCHCH(CHOH)-A-.
RO97-00561A 1994-09-28 1995-09-27 Compoziţie farmaceutică de aerosol RO118564B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419536A GB9419536D0 (en) 1994-09-28 1994-09-28 Medicaments
PCT/IB1995/000866 WO1996009816A1 (en) 1994-09-28 1995-09-27 Medicaments

Publications (1)

Publication Number Publication Date
RO118564B1 true RO118564B1 (ro) 2003-07-30

Family

ID=10762008

Family Applications (1)

Application Number Title Priority Date Filing Date
RO97-00561A RO118564B1 (ro) 1994-09-28 1995-09-27 Compoziţie farmaceutică de aerosol

Country Status (32)

Country Link
US (1) US5849265A (ro)
EP (1) EP0783302B1 (ro)
JP (1) JPH10506887A (ro)
KR (1) KR100375469B1 (ro)
CN (1) CN1084614C (ro)
AP (1) AP742A (ro)
AT (1) ATE187063T1 (ro)
AU (1) AU707922B2 (ro)
BG (1) BG62839B1 (ro)
BR (1) BR9509108A (ro)
CZ (1) CZ286356B6 (ro)
DE (1) DE69513671T2 (ro)
DK (1) DK0783302T3 (ro)
EE (1) EE03380B1 (ro)
ES (1) ES2140706T3 (ro)
FI (1) FI971279A7 (ro)
GB (1) GB9419536D0 (ro)
GE (1) GEP20002140B (ro)
GR (1) GR3032245T3 (ro)
HU (1) HU221856B1 (ro)
IS (1) IS1991B (ro)
MD (1) MD1900C2 (ro)
MX (1) MX9702149A (ro)
NO (1) NO313658B1 (ro)
NZ (1) NZ292995A (ro)
OA (1) OA10603A (ro)
PL (1) PL181453B1 (ro)
RO (1) RO118564B1 (ro)
RU (1) RU2157188C2 (ro)
SK (1) SK281519B6 (ro)
UA (1) UA47412C2 (ro)
WO (1) WO1996009816A1 (ro)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
ES2193069T3 (es) * 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
PT1305329E (pt) * 2000-08-05 2007-12-24 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
WO2002024623A2 (en) 2000-09-22 2002-03-28 Glaxo Group Limited Novel alkanoic acid derivatives
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
MY137522A (en) * 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
ES2307751T3 (es) * 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
GB0118364D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Compounds
HUP0401194A2 (hu) * 2001-08-03 2004-11-29 Glaxo Group Limited Új felületaktív anyagok, ezeket tartalmazó aeroszol készítmények és alkalmazásuk
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
MXPA04007899A (es) * 2002-02-13 2004-10-15 Glaxo Group Ltd Compuestos de acido carboxilico para usarse como agentes tensoactivos.
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP2275479A1 (en) 2003-08-11 2011-01-19 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US20080190418A1 (en) 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5529524A (en) * 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
JP2849471B2 (ja) * 1989-06-22 1999-01-20 アライアンス ファーマシューティカル コーポレイション 界面活性剤の性質を有するフッ素およびリン含有両親媒性分子
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
ES2071306T3 (es) * 1990-03-23 1995-06-16 Minnesota Mining & Mfg El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
CA2086096A1 (en) * 1990-06-27 1991-12-28 Robert A. Moris Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations

Also Published As

Publication number Publication date
CN1168630A (zh) 1997-12-24
FI971279L (fi) 1997-03-26
GR3032245T3 (en) 2000-04-27
EP0783302A1 (en) 1997-07-16
EP0783302B1 (en) 1999-12-01
GB9419536D0 (en) 1994-11-16
WO1996009816A1 (en) 1996-04-04
NZ292995A (en) 1998-10-28
CZ286356B6 (cs) 2000-03-15
BG101347A (en) 1997-12-30
PL319342A1 (en) 1997-08-04
HUT77377A (hu) 1998-04-28
MD1900C2 (ro) 2002-12-31
OA10603A (en) 2002-08-30
US5849265A (en) 1998-12-15
FI971279A0 (fi) 1997-03-26
EE03380B1 (et) 2001-04-16
FI971279A7 (fi) 1997-03-26
BR9509108A (pt) 1998-07-14
JPH10506887A (ja) 1998-07-07
AU3532195A (en) 1996-04-19
DK0783302T3 (da) 2000-05-29
PL181453B1 (pl) 2001-07-31
ES2140706T3 (es) 2000-03-01
IS4438A (is) 1997-03-10
KR970705981A (ko) 1997-11-03
IS1991B (is) 2005-02-15
MD970134A (ro) 1999-02-28
SK39397A3 (en) 1997-10-08
SK281519B6 (sk) 2001-04-09
DE69513671T2 (de) 2000-04-06
AP9700951A0 (en) 1997-04-30
MD1900B2 (ro) 2002-04-30
NO971422L (no) 1997-05-23
KR100375469B1 (ko) 2003-10-17
NO971422D0 (no) 1997-03-25
MX9702149A (es) 1998-04-30
CN1084614C (zh) 2002-05-15
GEP20002140B (en) 2000-06-25
CZ93697A3 (en) 1997-08-13
EE9700061A (et) 1997-08-15
DE69513671D1 (de) 2000-01-05
RU2157188C2 (ru) 2000-10-10
BG62839B1 (bg) 2000-09-29
ATE187063T1 (de) 1999-12-15
HU221856B1 (hu) 2003-02-28
NO313658B1 (no) 2002-11-11
AU707922B2 (en) 1999-07-22
AP742A (en) 1999-04-26
UA47412C2 (uk) 2002-07-15

Similar Documents

Publication Publication Date Title
RO118564B1 (ro) Compoziţie farmaceutică de aerosol
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
IL127352A (en) Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
GEP20022851B (en) Flash-Melt Oral Dosage Formulation
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
GB9425160D0 (en) Medicaments
NO20015083D0 (no) Pulverinnåndingsapparat for kombinert legemiddel
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
HUP0002691A2 (hu) Ciklezonid tartalmú gyógyászati aeroszol termékek
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
AU1890295A (en) Piperidines and pyrrolidines
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
MY127350A (en) Flash-melt oral dose formulations
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
TNSN01003A1 (fr) Appareil d'administration d'aerosols a comptage de dose dans des propulseurs hydrofluoroalcanes.
NZ508371A (en) Therapeutic anti-cold agent containing isomalt as an active ingredient
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
AU7775398A (en) Novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions
DE69918961D1 (de) Verbesserte inhalationspräparate